HE4, CA-125, and the ROMA Algorithm: An Educational Guide for Patients
Learn what HE4, CA-125, and the ROMA algorithm are, how they work together in ovarian cancer risk assessment, and how private blood testing in London can support your health awareness.
Understanding your health starts with knowing which biomarkers matter — and what they can tell you. For women who are health-conscious, proactive, or have a personal or family history that prompts extra vigilance, the ROMA algorithm, alongside the tumour markers HE4 and CA-125, offers a scientifically informed way to assess ovarian health risk. This educational guide explains what these blood markers are, how they are used together, and who may benefit from considering this type of private health screening in the UK.
What Are HE4, CA-125, and the ROMA Algorithm?
CA-125 (Cancer Antigen 125) is a protein found in the blood that is associated with ovarian tissue. Elevated levels can sometimes highlight certain conditions, including ovarian pathology, though it is not specific on its own.
HE4 (Human Epididymis Protein 4) is a more recently identified biomarker that may indicate ovarian cell activity. Research suggests HE4 can sometimes be elevated even when CA-125 is not, making it a valuable complement in assessment.
The ROMA algorithm (Risk of Ovarian Malignancy Algorithm) combines numerical values from both HE4 and CA-125, along with a woman’s menopausal status, to generate a single risk score. This score helps identify whether a woman falls into a lower or higher risk group for epithelial ovarian cancer.
Snippet Definition: The ROMA algorithm is a validated clinical tool that uses blood levels of HE4 and CA-125, together with menopausal status, to produce a risk score for epithelial ovarian cancer. It is used as part of a broader clinical assessment — not as a standalone diagnostic.
How Do HE4 and CA-125 Work Together?
Neither HE4 nor CA-125 should be interpreted in isolation. Each marker has its own strengths and limitations, but when used together within the ROMA framework, their combined value may be greater than when either marker is used alone.
Key Differences at a Glance
| Feature | CA-125 | HE4 |
|---|---|---|
| Type of Marker | Glycoprotein | Small protein |
| Sensitivity (premenopausal) | Moderate | Higher |
| Specificity | Can be affected by benign conditions | Generally more specific |
| Elevated in Benign Conditions? | Yes (endometriosis, fibroids, pregnancy) | Less commonly |
| Used in ROMA? | Yes | Yes |
| Best Use | Combined with HE4 | Combined with CA-125 |
CA-125 has been used in clinical settings for decades. However, it can sometimes be elevated due to non-cancerous conditions such as endometriosis, uterine fibroids, or even menstruation — which can occasionally lead to uncertainty when interpreted alone.
HE4, by contrast, tends to be more specific and is less likely to be raised by benign gynaecological conditions. When both markers are assessed together through the ROMA algorithm, the combined interpretation may provide a more balanced picture of risk.
Practical Insight: Neither of these markers is diagnostic on its own. A raised result may indicate a range of possibilities and always warrants appropriate follow-up with a qualified healthcare professional.
Who May Benefit from HE4, CA-125, and ROMA Testing?
This type of screening is informational — it supports health awareness rather than replacing clinical evaluation. Women who may find value in understanding their ROMA risk score include those who:
- Have a personal or family history of ovarian, breast, or related cancers
- Are experiencing unexplained abdominal bloating, persistent pelvic discomfort, or changes in bowel habits that have already been medically reviewed
- Are postmenopausal and seeking a broader picture of their health markers
- Are simply health-proactive and wish to build a baseline for ongoing monitoring
- Have had a previous elevated CA-125 result and wish to monitor over time alongside HE4
Please note that suitability for this type of testing depends on individual circumstances. If you are uncertain whether this testing is appropriate for you, we recommend consulting your GP or a qualified healthcare professional before proceeding.
Women who are premenopausal should be aware that elevated CA-125 is more common due to hormonal and gynaecological variation, which is precisely why the ROMA algorithm accounts for menopausal status in its calculation.
If you are experiencing new or persistent symptoms, it is important to seek appropriate medical advice without delay. This type of blood testing is designed to complement — not replace — professional clinical care.
What Does the ROMA Score Mean?
Once your HE4 and CA-125 values are obtained from a blood test, the ROMA algorithm calculates a percentage-based risk score. This score places you into one of two categories:
- Lower risk group — the score suggests a lower statistical probability of epithelial ovarian malignancy
- Higher risk group — the score suggests an elevated statistical probability, which would benefit from further clinical evaluation
It is important to understand that:
- A lower risk score does not rule out any condition
- A higher risk score does not confirm a diagnosis of cancer
- Results should always be reviewed in the context of your full medical history, symptoms, and any other relevant investigations
Practical Insight: A result from the ROMA algorithm is a risk stratification tool. It is most useful when reviewed by an appropriate healthcare professional who can consider it alongside your full clinical picture.
You can explore our CA-125 vs HE4 comparison guide to learn why combined interpretation is often preferred.
How Often Should HE4 and CA-125 Be Tested?
There is no universally agreed testing frequency for the general population. However, some considerations include:
- Baseline testing: Many women choose to have a baseline test to understand their starting values
- Annual monitoring: Some individuals with specific risk factors or a history of elevated markers may benefit from annual review
- Post-result follow-up: If a previous test showed elevated levels, retesting at an appropriate interval may be advised by your healthcare professional
Testing frequency should always be guided by your personal circumstances and, where results raise concern, by appropriate healthcare advice.
ROMA Testing in London: Accessing Private Health Screening
In London, private health screening is one option available to individuals who wish to access certain blood tests outside of NHS pathways, where NHS provision is appropriately targeted at symptomatic or clinically referred patients. Some individuals seeking routine, preventive, or reassurance-based testing may find private options more accessible for these specific purposes.
At Health Screening Clinic, we are a nurse-led clinic offering private blood testing and health screening for patients across London and the wider UK. Our ovarian risk screening package overview explains what a structured marker panel may include. We provide testing and reporting — helping you understand your results through clear, professional guidance.
We do not provide prescriptions, treatments, or specialist clinical services. Where results suggest the need for further evaluation, we will always advise you to seek appropriate medical care.
You can learn more about the score calculation pathway in our ROMA risk score methodology guide and continue reading through our educational blog library.
Understanding Your Results: A Patient’s Practical Guide
Receiving blood test results can feel overwhelming. Here is a simple framework for approaching your ROMA-related results:
- Review in context: Ask what your results mean alongside your age, menopausal status, and any symptoms
- Avoid single-point conclusions: One result at one point in time is rarely the full picture
- Track trends over time: For some individuals, monitoring changes in HE4 and CA-125 over months or years is more informative than a single reading
- Seek professional input: If your results fall into the higher risk category, or if you have any concerns, contact an appropriate healthcare professional promptly
Practical Insight: A raised marker can have many causes — some entirely benign. Equally, a lower score provides reassurance within a statistical framework rather than absolute certainty.
Frequently Asked Questions (FAQs)
What is the ROMA algorithm used for?
The ROMA algorithm is a validated risk assessment tool that uses blood levels of HE4 and CA-125, along with menopausal status, to calculate a risk score for epithelial ovarian cancer. It is used to help stratify patients into lower or higher risk groups and is not a standalone diagnostic test.
Is the ROMA algorithm the same as a cancer diagnosis?
No. The ROMA algorithm cannot diagnose cancer. It provides a risk stratification score that may indicate whether further clinical evaluation is warranted. A higher risk score should always be reviewed by an appropriate healthcare professional.
Can CA-125 be elevated without cancer?
Yes. CA-125 can sometimes be elevated due to benign conditions including endometriosis, uterine fibroids, pelvic inflammatory disease, or even during menstruation. This is one reason why CA-125 is more informative when interpreted alongside HE4 using the ROMA algorithm.
What is HE4 and how is it different from CA-125?
HE4 (Human Epididymis Protein 4) is a biomarker that tends to be more specific than CA-125 and is less frequently elevated in benign gynaecological conditions. It is particularly useful in premenopausal women and adds significant value when combined with CA-125 in the ROMA calculation.
Who should consider HE4 and CA-125 blood testing?
Women who are health-proactive, have a personal or family history of related conditions, are postmenopausal, or have had previously elevated CA-125 results may find this testing informative. Suitability depends on individual circumstances and we recommend discussing with a GP or qualified healthcare professional if you are uncertain. This testing is educational and intended to complement — not replace — professional clinical care.
How is the ROMA score calculated?
The ROMA score is calculated using a mathematical formula that incorporates the serum values of HE4 and CA-125 alongside the patient’s menopausal status. The output is a percentage-based risk score that places the individual in a lower or higher risk category for epithelial ovarian cancer.
Can I have HE4 and CA-125 tested privately in London?
Yes. Private nurse-led clinics in London can offer HE4 and CA-125 blood testing as part of women’s health screening services. Our ovarian risk blood-test explainer outlines what these markers can and cannot indicate. Results are reported clearly to help you understand your health picture and take appropriate next steps.
How long does it take to receive ROMA test results?
Turnaround times vary by provider. At a private clinic, results are typically available within a few working days. You should always ensure your results are accompanied by a clear written report explaining the values and their significance.
Does a lower ROMA score mean I am free from ovarian cancer?
No. A lower ROMA score indicates a lower statistical probability within the test framework, but it does not rule out any condition. It should be considered as one piece of information within your broader health picture and should not replace regular wellbeing checks or clinical advice.
What should I do if my ROMA score is in the higher risk group?
If your ROMA score falls in the higher risk group, it is important not to panic — many women with elevated scores do not have cancer. You should seek appropriate medical advice promptly so that further evaluation can be arranged. Your nurse or healthcare professional can guide you on the most appropriate next steps.
A Final Note on Proactive Health Awareness
Knowledge is one of the most powerful tools in health management. Understanding biomarkers like HE4 and CA-125, and how the ROMA algorithm interprets them together, allows you to approach your health with greater clarity and confidence.
At Health Screening Clinic, we believe that proactive, informed screening supports better health decisions. Our nurse-led team is here to support your health awareness journey through professional blood testing and clear, educational reporting.
If you are considering HE4, CA-125, or ROMA testing, our HE4 specificity guide for premenopausal women can help you decide what to discuss at booking. There is no obligation to proceed, and all decisions should be guided by your individual health needs and the advice of an appropriate healthcare professional.
EEAT Authority Statement
Educational content only; not medical advice, treatment, or diagnosis.
HE4, CA-125, and ROMA are risk-assessment tools and must be interpreted clinically.
Health Screening Clinic provides testing and reporting services only.
Content is prepared with GMC, CQC, and ASA communication standards in mind.
Seek prompt medical review for persistent symptoms or concerning results.